

AD\_\_\_\_\_

Award Number: **W81XWH-09-1-0583**

TITLE: **Deregulation of miRNAs Contributes to Development and Progression of Prostate Cancer.**

PRINCIPAL INVESTIGATOR: **Ralph W. deVere White, M.D.**

CONTRACTING ORGANIZATION: **University of California,  
Davis. CA 95616**

REPORT DATE: **August 2010**

TYPE OF REPORT: **Annual**

PREPARED FOR: **U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012**

DISTRIBUTION STATEMENT:

**Approved for public release; distribution unlimited**

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

**REPORT DOCUMENTATION PAGE**

*Form Approved  
OMB No. 0704-0188*

The public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number.

**PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE (DD-MM-YYYY) 01-08-2010	2. REPORT TYPE Annual	3. DATES COVERED (From - To) 1 AUG 2009 - 31 JUL 2010
---	--------------------------	--

4. TITLE AND SUBTITLE Deregulation of miRNAs Contributes to Development and Progression of Prostate Cancer.	5a. CONTRACT NUMBER
	5b. GRANT NUMBER W81XWH-09-1-0583
	5c. PROGRAM ELEMENT NUMBER

6. AUTHOR(S) Ralph W. deVere White, MD	5d. PROJECT NUMBER
	5e. TASK NUMBER
	5f. WORK UNIT NUMBER

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of California, Davis, CA 95616	8. PERFORMING ORGANIZATION REPORT NUMBER
--	--

9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012	10. SPONSOR/MONITOR'S ACRONYM(S)
	11. SPONSOR/MONITOR'S REPORT NUMBER(S)

12. DISTRIBUTION/AVAILABILITY STATEMENT  
Approved for public release; distribution unlimited

13. SUPPLEMENTARY NOTES

14. ABSTRACT  
The overall hypothesis of our proposal is that miR-125b acts as an oncogene, contributing to the development and progression of prostate cancer. In this grant, we proposed to test the ability of aberrantly-expressed miR-125b to promote tumorigenesis and to induce AI growth in three specific aims. In the first year, our focus was on Aim 1: to validate targets of miR-125b in prostate cancer. We have found that i) miR-125b directly targets three key pro-apoptotic molecules: p53, Puma and Bak1, and ii) AR signaling down-regulates p53, Puma and Bak1 via miR-125b in CaP cells. Our results obtained in the first year have provided new insight into the molecular mechanisms related to tumorigenesis and CR growth of CaP.

15. SUBJECT TERMS  
miRNA, tumorigenesis, oncogene, prostate cancer, Bak1, Puma p53

16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			USAMRMC 19b. TELEPHONE NUMBER (Include area code)

## Table of Contents

	<u>Page</u>
<b>Introduction</b>	<b>4</b>
<b>Body</b>	<b>4</b>
<b>Key Research Accomplishments</b>	<b>6</b>
<b>Reportable Outcomes</b>	<b>6</b>
<b>Conclusion</b>	<b>6</b>
<b>References</b>	<b>6</b>
<b>Appendices</b>	<b>8</b>

## INTRODUCCION

The focus of this research is on the Dereglulation of miRNAs and how it contributes to the development and progression of prostate cancer. Our overall hypothesis is that *miR-125b* acts as an oncogene, contributing to the development and progression of prostate cancer. In this study, we proposed to test the ability of aberrantly-expressed *miR-125b* to promote tumorigenesis and to induce AI growth in three specific aims. The first aim is to elucidate the mechanism by which *miR-125b* contributes to pathogenesis of prostate cancer. We proposed to validate targets of *miR-125b* in prostate cancer (CaP). The second aim is to evaluate the effects of *miR-125b* on prostatic tumorigenesis and AI growth. We will determine the influence of *miR-125b* on CaP in nude mice. The third aim is to determine the application of *miR-125b* as a biomarker for prostate cancer. We will detect the abundance of *miR-125b* in clinical prostate samples and determine whether the expression of *miR-125b* correlates to the outcome of patients with CaP. Here, we report the completion during our first year.

### Research and results (body)

In the first year, our focus was on Aim 1: to validate targets of *miR-125b* in prostate cancer. The following studies have been performed and these results have been obtained.

1. *Identification of miR-125b targets.* In preliminary study, we observed that *miR-125b* is upregulated in CaP and stimulates proliferation of CaP cells in the absence of androgens. In order to gain insight into the mechanism(s) through which *miR-125b* promotes CaP cell growth, we utilized a bioinformatics approach to identify its potential targets. For this, we compiled a database of the computationally-predicted *miR-125b* target sites (from MSKCC) and then used it as an index to mine a gene expression profile composed of transcripts that were differentially-expressed as a result of transient overexpression of *miR-125b* in CaP cells. In this manner, candidate direct targets are extracted from the entire dataset, which more than likely also contained transcripts regulated as a secondary response. The resulting putative, CaP-relevant *miR-125b* targets were then classified based upon Gene Ontology terms in order to determine the mRNAs whose suppression was most likely responsible for the alteration in one or more biological processes. A total of eight genes were identified that contain *miR-125b*-binding sites in their 3'UTRs (**Table I in Appendices**), including Bak1 that was previously validated as a *miR-125b* target by us (1) and others (2), and was used as a control in this study. Of these, p53, Puma and Bak1, which are functionally inactivated either by mutation and/or dysregulation, have been reported to play important roles in the initiation and progression of CaP. The other five genes are potential tumor or metastasis suppressors in other cancer types, including myotubularin related protein 3 (*MTMR3*) (3), BRCA1 associated protein-1 (*BAP1*) (4), sphingosine-1-phosphate lyase 1 (*SGPL1*) (5), aryl-hydrocarbon receptor repressor (*AHRR*) (6) and sialidase 1 (lysosomal sialidase) (*NEU1*) (7). Their involvement in CaP remains to be defined.

2. *miR-125b binds to the 3'-UTRs of p53 and PUMA.* Mature miRNAs negatively regulate gene expression by binding to the 3'-UTRs of target transcripts mediated by the complementarity of their 5'-end seed sequences (*i.e.*, nucleotides 2-8 or 2-7) with miRNA-binding site sequences. To validate that *miR-125b* negatively regulates *p53* and *PUMA*, we determined whether the putative *miR-125b* binding sites in their 3'-UTRs are responsible for regulation by *miR-125b*. These 3'-UTR fragments containing the binding site were separately cloned into the pRIM reporter-luciferase vector (Ambion). The 3'-UTR fragments without the binding site were used as negative controls. These reporter vectors were co-transfected with synthetic miR-125b mimic (miR-125bm) into the *miR-125b*-null DU145 cells for measuring luciferase (luc) activity. As shown in **Fig. 1 in Appendices**, cotransfection resulted in a 57% and 45% reduction of the reporter activity for *p53* and *PUMA*, respectively. These results provide experimental evidence that the 3' UTRs of *p53* and *PUMA* are targets of *miR-125b*.

3. *miR-125b downregulates the expression of p53 and Puma.* The effect of *miR-125b* on the expression of *p53* and *Puma* was further evaluated by the following experiments. We first determined whether *miR-125b* downregulates the expression of *p53* and *Puma*. LNCaP cells were transfected with 50 nM of miR-125bm and 24 hours later received irradiation (IR) of 10 Gys. Eight hours after IR, cells were harvested for Western blot analysis and immunostaining. Western blotting exhibited that IR significantly enhanced the cellular level of *p53*

and its two effectors, p21 and Puma. Treatment with synthetic miR-125bm dramatically decreased the basal p53 level and IR-stimulated p53 expression (**Fig. 2A in Appendices**). As expected, miR-125bm-induced p53 downregulation resulted in a marked decrease in the p21 and Puma levels. miR-125bm also represses the expression of Bak1 (**Fig. 2A in Appendices**). Additionally, we performed an immunostaining of p53 and Puma. Similar to Western blot assay, IHC demonstrated that ectopic expression of miR-125bm induced significant reduction of these proteins, and the representative results are shown in **Fig. 2B in Appendices**.

The analysis of the regulation of Puma by *miR-125b* in LNCaP cells is complicated by the expression of p53 that itself is an inducer of Puma. Thus, it is difficult to discern whether the downregulation of Puma is due to direct effect of *miR-125b* or to the decrease of p53 caused by *miR-125b*. We therefore utilized the p53-negative PC3 cells. Cells were treated with miR-125bm and then with 100  $\mu$ M resveratrol that was reported to upregulate Puma and Bak1 in PC3 cells (8). Western blot analysis shows that transfection with miR-125bm resulted in a significant reduction of resveratrol-stimulated Puma and Bak1 (**Fig. 2C in Appendices**), which validates the direct regulation of Puma by *miR-125b*. Taken together, these results indicate that *miR-125b* targets p53 and Puma in CaP cells, and *miR-125b* targets Puma in both p53 positive and null CaP cells.

4. *Androgen downregulates p53 and Puma.* We preliminarily found that androgen upregulates *miR-125b* that downregulates Bak1 (1), and thus asked whether androgen can downregulate p53 and Puma. To address this issue, LNCaP cells were treated with R1881 androgen or anti-miR-125b. Western blot analysis was performed to determine the expression levels of p53 and Puma. When compared with untreated and vehicle-treated cells, R1881 induced a significant reduction of basal p53 and Puma, as well as Bak1 as control, while ectopic expression of anti-miR-125 increased these proteins (**Fig. 3A in Appendices**). In addition, LNCaP cells were treated with R1881 for 48 hours followed by irradiation with 10 Gys. It was found that R1881 treatment resulted in a reduction of irradiation-stimulated upregulation of p53 and Puma (**Fig. 3B in Appendices**). These results further support our hypothesis that androgen signaling regulates p53, Puma and Bak1.

5. *Casodex stimulates the expression of miR-125b in androgen-independent CaP cell lines.* The AR antagonist Casodex (CDX, or bicalutamide) is clinically used for treatment of castration-resistant (CR) CaPs. This compound inhibited the androgen-induced expression of *miR-125b* in LNCaP cells (data not shown). Since Casodex stimulated the CR growth (9, 10) and induced the expression of PSA in AI LNCaP subline (11, 12), we tested the role of Casodex in regulating *miR-125b* in androgen-independent CaP cell lines *cds1* and *22Rv1*. *In situ* hybridization (ISH) assays showed that treatment of both cell lines with 5.0  $\mu$ M Casodex stimulated *miR-125b* expression to a level similar to that in R1881-treated cells. The representative results obtained in *cds1* cells are shown in **Fig. 4A in Appendices**. We previously found that the p160 coactivator TIF2 modulated the function of a casodex-liganded AR, and knockdown of TIF2 using a shRNA to TIF2 (shTIF2) decreased Casodex's agonistic effect (11). We thus determined that shTIF2 inhibits the Casodex-stimulated expression of *miR-125b*. It was found that infection with 5 MOIs (multiplicities of infection) of adeno-shTIF2 resulted in marked reduction of Casodex-induced *miR-125b* expression in *cds1* (**Fig. 4A in Appendices**) and *22Rv1* (data not shown). Infection with only shTIF2 did not alter the basal level of *miR-125b* and the adeno-shGFP control did not reduce Casodex-stimulated expression of *miR-125b* (data not shown). To quantitate the *miR-125b* signal, we used a fluorescence microscope to capture mean fluorescent intensity from >50 cells. Both R1881 and CDX induced a >2-fold increase in the fluorescence signal in *cds1* and *22Rv1*. shTIF2 was able to block the CDX-stimulated increase in *miR-125b* (**Fig. 4B in Appendices**). These data suggest that aberrantly activated AR regulates the expression of *miR-125b* and that p160 coactivators are likely involved in regulation of *miR-125b* expression.

6. *Upregulation of miR-125b by EGF.* Studies have revealed that in addition to androgens some protein growth factors (GFs) binding to specific membrane receptors (GFRs) activate multiple downstream signaling pathways, resulting in AR activation (13, 14). We are very interested in determining whether protein factors are able to upregulate the expression of *miR-125b* in an androgen-depleted environment. Since epidermal growth factor (EGF) and its membrane receptor HER2 are frequently upregulated in advanced stages of CaP (15), we thus evaluated the effect of EGF on the expression of *miR-125b* in androgen-dependent LNCaP cells and

androgen-independent cds1 cells. Cells were treated with 20 ng/ml EGF for 2 days and RNA isolated. The level of *miR-125b* was measured by qRT-PCR. It was found that EGF stimulated the level of *miR-125b* in both LNCaP and cds1 cells (**Fig 5 in Appendices**).

## KEY RESEARCH ACCOMPLISHMENTS

In our first year, we have obtained exciting results. The key accomplishments are that *1*) oncogenic *miR-125b* directly targets three key pro-apoptotic molecules; *2*) some factors (like Casodex and EGF) that abnormally activate androgen receptor (AR) in the absence of androgens can stimulate the expression of *miR-125b* in CaP cells; and *3*) our data strongly suggest that there an AR-*miR-125b* signaling pathway in CaP cells that may mediate CR growth of CaP cells.

## REPORTABLE OUTCOMES

### *Published abstract*

- Xu-Bao Shi, Lingru Xue, Clifford Tepper, Ralph W. deVere White. Suppression of key apoptosis-related molecules by *miR-125b* contributes to androgen-independent growth of prostate cancer cells. AACR 101<sup>st</sup> Annual Meeting 2010, April 17-21, 2010 Washington, DC.

## CONCLUSION

Our results obtained in the first year demonstrated that *miR-125b* directly targets three key pro-apoptotic molecules: p53, Puma and Bak1. These data also provide strong evidence showing that androgen- or non-androgen-stimulated AR signaling down-regulates p53, Puma and Bak1 via *miR-125b* in CaP cells. Therefore, this study sheds new insight into the molecular mechanisms related to tumorigenesis and CR growth of CaP.

In the next year, we will focus on addressing the ability of aberrantly-expressed *miR-125b* to promote prostatic tumorigenesis and to induce AI growth.

## REFERENCES

1. Shi XB, Xue L, Yang J, Ma AH, Zhao J, Xu M, Tepper CG, Evans CP, Kung HJ, deVere White RW. An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. *Proc Natl Acad Sci U S A* 2007;104:19983-8.
2. Zhou M, Liu Z, Zhao Y, Ding Y, Liu H, Xi Y, Xiong W, Li G, Lu J, Fodstad O, Riker AI, Tan M. MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. *J Biol Chem*;285:21496-507.
3. Yoo YD, Cho SM, Kim JS, Chang YS, Ahn CM, Kim HJ. The human myotubularin-related protein suppresses the growth of lung carcinoma cells. *Oncol Rep* 2004;12:667-71.
4. Jensen DE, Rauscher FJ, 3rd. BAP1, a candidate tumor suppressor protein that interacts with BRCA1. *Ann N Y Acad Sci* 1999;886:191-4.
5. Bandhuvula P, Saba JD. Sphingosine-1-phosphate lyase in immunity and cancer: silencing the siren. *Trends Mol Med* 2007;13:210-7.
6. Zudaire E, Cuesta N, Murty V, Woodson K, Adams L, Gonzalez N, Martinez A, Narayan G, Kirsch I, Franklin W, Hirsch F, Birrer M, Cuttitta F. The aryl hydrocarbon receptor repressor is a putative tumor suppressor gene in multiple human cancers. *J Clin Invest* 2008;118:640-50.
7. Uemura T, Shiozaki K, Yamaguchi K, Miyazaki S, Satomi S, Kato K, Sakuraba H, Miyagi T. Contribution of sialidase NEU1 to suppression of metastasis of human colon cancer cells through desialylation of integrin beta4. *Oncogene* 2009;28:1218-29.
8. Shankar S, Siddiqui I, Srivastava RK. Molecular mechanisms of resveratrol (3,4,5-trihydroxy-trans-stilbene) and its interaction with TNF-related apoptosis inducing ligand (TRAIL) in androgen-insensitive prostate cancer cells. *Mol Cell Biochem* 2007;304:273-85.
9. Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A, Bartsch G, Utermann G, Schneider MR, Parczyk K, Klocker H. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. *Br J Cancer* 1999;81:242-51.


10. Hobisch A, Hoffmann J, Lambrinidis L, Eder IE, Bartsch G, Klocker H, Culig Z. Antagonist/agonist balance of the nonsteroidal antiandrogen bicalutamide (Casodex) in a new prostate cancer model. *Urol Int* 2000;65:73-9.
11. Shi XB, Xue L, Zou JX, Gandour-Edwards R, Chen H, deVere White RW. Prolonged androgen receptor loading onto chromatin and the efficient recruitment of p160 coactivators contribute to androgen-independent growth of prostate cancer cells. *Prostate* 2008;68:1816-26.
12. Hara T, Miyazaki J, Araki H, Yamaoka M, Kanzaki N, Kusaka M, Miyamoto M. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. *Cancer Res* 2003;63:149-53.
13. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. *Cancer Res* 1994;54:5474-8.
14. Kung HJ, Evans CP. Oncogenic activation of androgen receptor. *Urol Oncol* 2009;27:48-52.
15. Shi XB, Ma AH, Tepper CG, Xia L, Gregg JP, Gandour-Edwards R, Mack PC, Kung HJ, deVere White RW. Molecular alterations associated with LNCaP cell progression to androgen independence. *Prostate* 2004;60:257-71.

## Appendices


Table I. Genes directly targeted by *miR-125b* in LNCaP cells

Name	Fold change*	Function	<i>miR-125b</i> binding site at 3'UTR
p53	-1.3	Tumor suppressor	733-739
Puma	-2.5	Pro-apoptosis	24-30
Bak1	-2.0	Pro-apoptosis	630-637
Mtmr3	-1.4	Tumor suppressor	941-947
Bap1	-1.6	Tumor suppressor	580-586
Sgpl1	-1.9	Tumor suppressor	1586-1592
Ahrr	-1.5	Tumor suppressor	1275-1281
Neu1	-1.7	Metastasis suppressor	331-337


\*Fold change: signal in *miR-125* treated cells/that in miR-NC-treated cells.




**Fig. 1.** Luciferase analysis of *miR-125b* binding to the 3'UTRs of *p53* and *PUMA* in DU145 cells. Individual truncated 3'UTRs of *p53* and *PUMA* were used as controls (no binding site) in these experiments. The assay was repeated three times with each assay being performed in three wells and similar results were obtained each time. The representative results are shown as  $M \pm SD$  ( $n = 3$ ).




**Fig. 2.** *miR-125b* targets pro-apoptotic genes. **A)** Western blot analysis of the expression of p53, p21, Puma and Bak1 in miR-125bm-treated LNCaP cells. Cells were first transfected with 50 nM of chemically-modified miR-125b mimic (125bm) and 24 hours later irradiated with 10 Gys (IR). Eight hours after irradiation, cells were lysed and protein was extracted for Western blot analysis of p53, p21, Puma and Bak1. The controls include untreated cells (untreat.) and miRNA negative control (miR-NC)-treated cells. **B)** Detection of the expression levels of p53, Puma and Bak1 in LNCaP cells by immunostaining. LNCaP cells were grown for 24 hours on sterile slides in 100-mm Petri dishes in 10% FBS medium. Cells were first transfected with 50 nM of chemically-modified miR-125bm and 24 hours later irradiated with 10 Gys. Eight hours later, cells were fixed. p53, Puma or Bak1 were stained using specific 1st antibodies followed by a HRP-labeled 2nd antibody. Then, addition of the substrate (DAB) led to generate the brown color. The enzymatic approach shows that p53 locates mainly in nuclei, and Puma and Bak1 in cytoplasm. The white squares indicate the areas of magnified images. **C)** PC3 cells were transfected with 50 nM of miR-125bm (125bm) and 24 hours later treated with 100 μM resveratrol. Cells were lysed next day and protein was isolated for Western blot analysis of Puma and Bak1. Untreated cells (untreat.) and vehicle-treated cells are used as controls. β-actin is a loading control.



**Fig. 3.** Effect of androgen on the expression of p53, Puma and Bak1. **A)** LNCaP cells were treated with 5.0 nM of R1881 or 100 nM anti-miR-125b (anti-125b) for 48 hours. Subsequently cells were harvested for Western blot analysis of p53, Puma and Bak1. **B)** LNCaP cells were treated with 5.0 nM R1881 for 48 hours followed by 10 Gys of irradiation (IR). Eight hours after irradiation, the cellular levels of p53 and Puma were analyzed by Western blotting. Controls include untreated cells (untreat.) and ethanol vehicle. β-actin is a loading control.



**Fig 4.** ISH assays of casodex-stimulated expression of *miR-125b*. **A)** *miR-125b* in *cds1* that were treated with vehicle, 1.0 nM R1881, 5.0 μ M Casodex (CDX) or CDX&shTIF2. The squares indicate areas where the images are magnified. **B)** Quantitation of *miR-125b* signal in *cds1* and *22Rv1*.



**Fig 5.** qRT-PCR analysis of *miR-125b* level in LNCaP and *cds1* cells treated with 20 ng/ml EGF for 2 days. R1881 is positive control and U6 small RNA is negative control.